From glaucoma to dry eye, millions of Brits rely on eye drops daily. The UK ophthalmic drugs market report by MRFR shows that anti‑inflammatory drugs are the largest segment, but antiglaucoma drugs are the fastest‑growing. The market is $2.06 billion and will hit $3.8 billion by 2035, growing at 5.73% CAGR. Why the rise? Because an aging population means more eye disease.

What's driving growth? Eye drops are the largest formulation, but injectables are the fastest‑growing — especially for retinal diseases like age‑related macular degeneration (AMD). The UK ophthalmic drugs market analysis highlights that topical administration is the largest route, but intravitreal injections are growing fast — as anti‑VEGF drugs (Lucentis, Eylea) become standard for wet AMD.

What's new? Sustained‑release implants (e.g., Ozurdex, Iluvien) that last months, reducing injection frequency. Also, preservative‑free formulations for dry eye — less irritation, better compliance.

The bottom line: if you have an eye condition, don't just grab any drop. Ask your pharmacist or ophthalmologist. The right drug can save your sight.